Hospital General Universitario de Valencia -ko ikertzaileekin lankidetzan egindako argitalpenak (13)

2021

  1. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2020

  1. Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials

    AIDS and Behavior, Vol. 24, Núm. 12, pp. 3473-3481

  2. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2017

  1. Eradication of hepatitis C virus and non-liver-related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection

    Hepatology, Vol. 66, Núm. 2, pp. 344-356

2016

  1. The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, but Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial

    Medicine (United States), Vol. 95, Núm. 6

2015

  1. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus

    Clinical Infectious Diseases, Vol. 60, Núm. 6, pp. 950-958

2014

  1. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients

    AIDS, Vol. 28, Núm. 9, pp. 1279-1287

2013

  1. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus

    Journal of Hepatology, Vol. 58, Núm. 6, pp. 1104-1112

2012

  1. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with hiv and hepatitis c virus

    Clinical Infectious Diseases, Vol. 55, Núm. 5, pp. 728-736

2011

  1. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 12, pp. 2843-2849

2009

  1. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

    Hepatology, Vol. 50, Núm. 2, pp. 407-413

2007

  1. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: The CORAL-1 multicentre pilot study

    Journal of Viral Hepatitis, Vol. 14, Núm. 10, pp. 704-713

2004

  1. Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations

    Journal of Viral Hepatitis